Top SMid Biotechnology Stocks: JPMorgan’s Latest Pick

JPMorgan retained Olema Oncology on its Analyst Focus List after the stock fell about 25% following AstraZeneca's statistically insignificant SERENA-4 trial, calling the selloff an overreaction. The firm sees potential for Olema shares to reach the mid-$20s or higher if the Phase 3 OPERA-01 trial is positive in both ESR1-mutant and wild-type populations, versus downside to the mid-single digits. OPERA-01 data are expected in Q1 2027; Olema recently reported a Q2 loss of $0.61 per share, missing estimates, while completing enrollment for the pivotal study.

Analysis

OLMA is now a binary, capital-structure-sensitive oncology option rather than a clean sympathy trade on a competitor’s result. The key question is whether the selloff has pushed enterprise value below the risk-adjusted value of palazestrant’s later-line opportunity; that cannot be established without current cash, quarterly burn, dilution capacity, and the trial’s event timeline. A long-duration catalyst in 1Q27 leaves the shares vulnerable over the next 6-12 months to financing risk, sector-rate sensitivity, and intermittent de-risking by generalist holders.

AZN’s result is not necessarily a direct negative read-through for OLMA: cross-trial efficacy will depend on patient mix, prior CDK4/6 exposure, biomarker prevalence, and especially the performance of the common control regimen. If the control arm underperforms at the full-data presentation, the apparent failure may reflect trial design or an unexpectedly strong comparator rather than class-level weakness; conversely, a robust control arm would raise the efficacy bar and compress OLMA’s probability-of-success assumptions. The nearer catalyst is therefore the complete AZN dataset, not the distant pivotal readout.

Consensus appears too willing to anchor on historical early-stage progression-free-survival figures, which are particularly prone to selection bias and are not sufficient to underwrite a registrational valuation. The upside case requires not only statistical success but clinically credible benefit in both biomarker cohorts, tolerability that supports duration of therapy, and a credible commercial position against incumbent endocrine combinations. A positive data outcome could drive a sharp multiple re-rating, but failure would likely leave residual value determined primarily by cash rather than pipeline optionality.

Key Decisions for Investors

• Keep OLMA on a catalyst watchlist rather than initiate a full position until the next filing confirms cash runway through the 1Q27 readout without an intervening equity raise. If runway is less than 18 months, treat any rally into medical-conference data as a potential financing window and avoid unhedged long exposure.
• For a biotech sleeve, consider a starter OLMA position only after full SERENA-4 data if control-arm progression-free survival and biomarker composition support the differentiated-mechanism thesis; size at 25-50 bps NAV maximum given binary downside. Add only if the stock remains near cash-adjusted value and the data do not raise the required efficacy threshold.
• Use XBI as the hedge against broad small-cap biotech and real-yield risk: long OLMA / short XBI is preferable to outright long exposure for investors specifically underwriting palazestrant. Reassess if 10-year real yields rise materially or XBI liquidity weakens, since pre-revenue biotech beta can dominate idiosyncratic fundamentals over the next 1-3 months.
• Do not short AZN on this event alone. The relevant oncology program is unlikely to be material to AZN’s diversified earnings base; a tradeable negative case would require evidence that the result impairs a broader franchise strategy or forces a meaningful revision to pipeline expectations.